TP53 and urinary bladder carcinoma: Beyond viral and TP53-related alterations, emerging genomic changes such as Loss of Y chromosome (LOY) have recently been implicated in urological cancers, including prostate and bladder cancer, where they are associated with immune dysregulation and adverse outcomes.